Corcept Therapeutics, Inc. (NASDAQ:CORT)
CAPS Rating:
A pharmaceutical company which is engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases.
Growing the love for investing
A pharmaceutical company which is engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Corcept continues to flog Corlux, its pipeline in a teacup. The stock continues to get diluted as the phase III study of Corlux in Cushing's syndrome approaches a topline data release in mid-2010. As there is minimal clinical data for efficacy in Cushing's to support the phase III study, I'm not going to get my buffalo hump in a lather over it. The phase III study in psychotic depression is a joke, with obvious enrollment issues in the wake of multiple prior failures for the same indication.
I wouldn't count mifepristone out wrt treating Cushing's syndrome, or at least acute cortisol-induced psychosis. Especially in non-iatrogenic cases, when it me be difficult to treat the primary cause of Cushing's, perhaps if it's caused by an andrenal neoplasm, mifepristone may be the best option.